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Summary--Two transplantable, androgen dependent prostate tumor models of human origin, 
PC-82 and PC-EW, were used to study the effect of low androgen levels and adrenal androgens 
on prostate tumor cell proliferation. Tumor load of the PC-82 and PC-EW tumors could be 
maintained constant when plasma testosterone l vels were 0.8 and 0.9 nmol/l, respectively, 
corresponding with an intratissue 5ct-dihydrotestosterone lev l of 3-4pmol/g tissue. This 
critical androgen level for prostate tumor growth stimulation amounted to 2-3 times the 
castration level and proved to be similar for both tumor models. Relatively high levels of 
androstenedione resulted in physiological levels of plasma testosterone causing androgen 
concentrations in PC-82 tumor tissue exceeding the critical level for tumor growth. These 
results indicate that submaximal suppression of androgens can stop tumor growth in these 
prostate tumor models. 
INTRODUCTION 
Endocrine treatment of prostate cancer patients 
alone, whatever therapy regimen used, cannot 
anticipate the relapse phenomenon which 
always follows the initial response of the tumor 
to hormonal therapy [1]. It has been questioned 
whether this transient response to hormonal 
treatment results from a selective outgrowth 
of (pre-existing) androgen independent clones of 
cells [2, 3] or is due to an insufficient ablation of 
androgens [4, 5]. In men, androgens of adrenal 
origin, remaining in circulation after castration, 
may compensate for the castration-induced de- 
cline in intraprostatic androgen concentration 
in part [6]. Many studies, both experimental nd 
clinical, have been conducted in an attempt 
to reveal whether a more complete androgen 
ablation than obtained by castration alone, 
might yield a more favorable result in the 
treatment of prostatic ancer. To date, there is 
no definite answer to this question. 
In order to study this point in more detail, 
two androgen dependent prostate tumor models 
of human origin, PC-82 and PC-EW, were used 
to investigate the relationship between growth 
activity of prostatic carcinoma tissue and per- 
ipheral and tissue testosterone (T) and 5~- 
dihydrotestosterone (DHT) concentrations. In 
addition, the role of the adrenal androgens 
androstenedione (A) and dehydroepiandros- 
terone (DHEA) in prostate tumor growth 
stimulation was studied. 
EXPERIMENTAL 
Tumor model characteristics 
Both tumors used in this study, PC-82 and 
PC-EW, are of human origin and serially trans- 
plantable in nude mice. The PC-82 tumor model 
is derived from a primary, moderately differen- 
tiated adenocarcinoma of the prostate[7, 8]. 
The PC-EW tumor originates from a lymph 
node metastasis and is composed of poorly and 
moderately differentiated carcinoma [9]. These 
tumor models share many of the properties een 
in clinical prostate cancer. Although tumor take 
(85%) and tumor doubling time (18 days) are 
similar for both tumors, the PC-EW tumor 
regresses much faster after androgen withdrawal 
than the PC-82 tumor; tumor halftime being 8 
and 17 days, respectively. 
Manipulation of  plasma testosterone levels in 
mice 
Female or castrated male nude mice of the 
. . . . . . . . . . . . . . . . . . .  Balb/c background were routinely substituted 
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levels of T, in the low dose resubstitution studies 
Silastic implants (0.6 cm) were filled with either 
cholesterol (0%T) or with cholesterol mixed 
with different amounts of T (5, 10, 25 and 
100%T implants), resulting in various plasma T 
levels. 
Experimental protocol 
To study the effect of various levels of andro- 
gen on prostate tumor growth without influenc- 
ing tumor take, mice were transplanted with 
small fragments of tumor tissue and simul- 
taneously substituted with a standard ose of T 
(0.4cm length; resulting peripheral T level: 
10 nmol/l) to assure an optimal tumor take and 
tumor growth. When tumors were in the expo- 
nential phase of growth, implants were removed 
for a short period of time to deplete the tumor 
tissue of androgens. Because of the difference in 
regression rate, depletion periods of 12 and 5 
days were chosen for the PC-82 and PC-EW 
tumors, respectively. Subsequently, mice were 
resubstituted with implants containing various 
doses of T (Fig. 1). Tumor volume changes were 
followed weekly by caliper measurements. 
Tumor volume was calculated according to the 
formula 
V = 7t/6(dl x d2) 3'2, 
in which d~ and d 2 are two perpendicular tumor 
diameters. After 28 days mice were sacrificed 
and plasma and tumor tissue were collected. 
Substitution with adrenal androgens 
The ability of adrenal androgens to support 
prostate tumor growth was studied by implant- 
ing mice with A and DHEA packed in Silastic 
tubings. As the adrenal glands of mice do not 
produce androgens (results not shown), 
endogenous synthesis of adrenal androgens can- 
not interfere with adrenal androgen substitution 
in this model. Mice were treated according 
to the same protocol followed for the T 
supplementation experiments (Fig. I). 
Hormone stimations inplasma and tumor tissue 
T and DHT levels in tumor tissue were esti- 
mated in whole tissue homogenates after separ- 
lake/growth tissue 
tumor growth 
arrest 
t 
t t T 
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Fig. I. Protoco l  for the exper iments with PC-82 and PC-EW 
grown under  var ious androgen levels. 
ation of the androgens on silica columns as 
described by H/im/il~iinen et al. [11]. Plasma 
androgen content and separated androgen 
fractions from the tissue homogenates were 
analyzed by a radioimmunoassay[12]. This 
procedure has been described in more detail 
elsewhere [13]. 
Statistical procedure 
All data are expressed as the mean + standard 
error of the mean (SEM) with the number of 
animals in parentheses. All group differences 
were statistically analyzed using the Student 
t-test and were considered significant when 
P < 0.05. 
RESULTS 
Plasma and intratissue levels of androgen 
Substitution of female or castrated male mice 
with various doses of T resulted in plasma levels 
ranging from 0 to 20 nmol/1 (Table 1). These 
levels, as well as the growth response of 
the tumors, did not differ significantly between 
implanted females and castrated males. A sig- 
nificant correlation was observed between 
plasma T and intratumor DHT concentration 
for both tumor models (PC-82--r =0.87, 
n = 34, P < 0.001; PC-EW--r  = 0.69, n = 23, 
P < 0.05). In all substituted groups PC-EW 
tumor tissue had a significantly lower DHT 
content than PC-82 tumor tissue, whereas a 
similar castrate level of DHT (0%T) was found 
in both tumors. 
Threshold level for tumor growth stimulation 
A significant dose-response relationship 
between intratumor DHT concentration and 
tumor growth was observed in both the PC-82 
and PC-EW tumor models (r = 0.88, n = 39, 
P < 0.001; and r =0.91, n = 17, P < 0.001, re- 
spectively). Tumor growth in 10 and 25%T 
substituted mice was significantly retarded com- 
pared to the tumor growth observed in the 
100%T substituted mice. Maintenance of the 
Table I. Plasma T levels in mice bearing the PC-82 
or PC-EW tumor at the end of the experiment 
(28 days) 
Proportion of T Plasma level 
in implant (%T) of T (nmol/I) 
0 0.1 +0.03(18) 
5 0.6+_0.2 (12) 
10 1.3+_0.3 (17) 
25 4.5 _+ 1.0 (4) 
100 15.6 +_ 1.3 (8) 
Plasma T levels were significantly different between 
all groups (P < 0.05). 
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Fig. 2. Relat ionship between intratissue DHT content and 
PC-82 tumor  growth.  
PC-82 tumor was achieved at a plasma T level 
of 0.8 + 0.8 nmol/l, corresponding with intra- 
tissue T and DHT levels of 6-10 and 
3-4 pmol/g tissue (Fig. 2). Stabilization of the 
PC-EW tumor volume was observed at similar 
T levels (0.9 + 0.9 nmol/l) resulting in intra- 
tumor T and DHT concentrations of 5-9 and 
2-3 pmol/g tissue (Fig. 3). Both tumors showed 
a decline in tumor burden in 0%T substituted 
mice (0.1-0.2 nmol/1), which was comparable 
to the regression ormally seen in castrated 
animals. DHT threshold levels for growth 
stimulation of both PC-82 and PC-EW tumors 
were approx. 3 pmol/g tissue. 
PC-82 tumor growth with adrenal androgen 
substitution 
Supplementing mice with DHEA (peripheral 
levels: 9.2 + 1.7 nmol/l) did not result in any 
PC-82 tumor growth stimulation. The tumor 
regression observed in these mice was equal 
to that observed in the 0%T implanted mice 
(Table 2). Although plasma levels of T in 
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Fig. 3. Relat ionship between intratissue DHT content and 
PC-EW tumor growth. 
DHEA substituted mice were above the cas- 
tration level (1.2 + 0.2 nmol/1), intratissue 
androgen levels were not significantly different 
from those of castrated animals (data not 
shown). Substitution of A caused plasma T 
levels of 10.7 + 1.6 nmol/1 and accordingly in- 
duced an increase in PC-82 tumor volume which 
was significantly less than that observed in the 
100%T implanted mice (Table 2). 
DISCUSSION 
After castration of prostate cancer patients 
plasma levels of androgens decrease markedly, 
whereas relatively high levels of T and DHT 
remain present in the prostate [14]. Obviously, 
these levels originate from androgens ecreted 
by the adrenal glands and it is well-known that 
prostatic tissue is capable of metabolizing 
adrenal androgens into T and DHT [15]. In this 
study the relevance of these remaining levels of 
androgens for growth stimulation of human 
prostate tumor tissue was investigated. 
From the experiments presented here, it be- 
came evident hat growth of PC-82 and PC-EW 
prostate tumor tissue could be stimulated when 
Table 2. PC-82 tumor growth and plasma levels of DHEA, A and T in female nude mice 
supplemented with DHEA, A, 0 and 100%T 
Plasma level (nmol/l) Tumor volume 
Androgen DHEA A T (mm ~) 
0%T 0.7 + 0.2 (5) 0.9 _+ 0.3 (5) 0.3 + 0.1 (9) 60 + 4 (I 1) 
DHEA 9.2-t- 1.7(5) ~ ND 1.2+0.2(10) ~ 71 +4(11) 
A ND 13.5± 1.3(5)" 11.9_+ 1.4 (7) b 217_+15(8) b 
100%T ND ND 17.6 _+ 2.1 (3) 362 _+ 44(4) 
Mice were sacrificed at the end of the experiment (28 days). ND not detected. 
~Significantly different from 0%T (P < 0.05). 
bSignificantly different from 100%T (P < 0.05). 
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intratissue DHT exceeded approx. 3 pmol/g 
tissue. This intratumor level of DHT, which is 
2-3 times the level found in 0%T implanted or 
castrated mice, can be regarded as a threshold 
level for tumor growth stimulation[13], 
although, lower levels of androgen did result in 
a maximal reduction of tumor burden. 
The response of the PC-EW tumor to andro- 
gen depletion differs from that of the PC-82 
tumor, as PC-EW regresses much faster. In 
addition, PC-EW has considerably lower intra- 
tissue levels of DHT as compared to the PC-82 
tumor model (Figs 2 and 3). Remarkably, the 
critical level of intratissue DHT for tumor 
growth is similar for both tumor models. The 
question remains, however, whether all pro- 
static carcinomas do have a similar cut-off point 
for minimal stimulating androgen levels. The 
adrenal androgen DHEA could not prevent 
regression or could it activate growth in both 
tumor models. In contrast, A induced a marked 
increase in plasma T levels, resulting in high 
levels of intratissue T and DHT levels in the 
PC-82 tumor. These levels, which exceeded the 
threshold level for growth stimulation, caused 
the PC-82 tumor to grow accordingly (Table 2). 
It should be mentioned, however, that these 
plasma levels of A were above the levels nor- 
mally found in castrated men, as in a group of 
patients treated with an LHRH agonist A levels 
of 4-5 nmol/l were observed (own clinical data). 
Experiments with levels of A which are more 
close to the clinical situation are currently being 
carried out. 
After surgical or chemical castration of 
prostate cancer patients DHT levels in the pros- 
trate remain relatively high: in prostatic tissue 
of castrated prostate cancer patients average 
DHT levels of 4pmol/g were found[16, 17]. 
However, 7 out of the 38 patients had DHT 
levels > 6.5 pmol/g tissue, whereas the majority 
of the patients had DHT levels <4 pmol/g [18]. 
Intraprostatic concentrations of DHT found in 
a majority of prostate cancer patients after 
orchiectomy may therefore be considered low 
enough to prevent prostate tumor growth, 
whereas in only a few patients DHT levels 
exceed the level found to be stimulatory for the 
prostate tumor models PC-82 and PC-EW. 
In conclusion, the data presented in this paper 
indicate that partial androgen withdrawal can 
stop tumor growth in the prostate tumor models 
PC-82 and PC-EW. This indicates that total 
androgen ablation is not needed to prevent 
growth of these tumors. Relatively high plasma 
levels of A were found to be stimulatory for 
PC-82 tumor growth, which implies that adrenal 
androgens may be involved in clinical prostate 
cancer. 
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